ArticleNeurobiology of aging2017
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.
Open access · bronzeAbstract read
In one paragraph
Article in Neurobiology of aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.Annals of neurology · 2021Article
- Genetic and Environmental Factors Influence the Pleomorphy ofInternational journal of molecular sciences · 2021Review
- Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson's Disease.Frontiers in neurology · 2021Article
- Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 20 institutions in 19 countries.
Lisa WangCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tuebingen, Tuebingen, Germany.
Michael G HeckmanDivision of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
Jan O AaslyDepartment of Neurology, St Olavs Hospital and NTNU, Trondheim, Norway.
Grazia AnnesiInstitute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.
Maria BoziNeurology Department, Psychiatry Athens Hospital, Athens, Greece; 2nd Neurology Clinic, University of Athens, Attikon Hospital, Athens, Greece.
Sun Ju ChungDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Carl ClarkeSchool of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
David CrosiersNeurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Department of Neurology, University Hospital Antwerp, Antwerp, Belgium.
Gertrud EcksteinHelmholtz Zentrum München, German Research Centre for Environmental Health (Gmbh), Neuherberg, Germany.
Gaetan GarrauxDepartment of Neurology, Cyclotron Research Centre, University of Liège, Liège, Belgium.
Georgios M HadjigeorgiouDepartment of Neurology, Faculty of Medicine, University of Thessaly and Institute of Biomedical Research and Technology, CERETETH, Larissa, Greece.
Nobu HattoriDepartment of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Beom JeonInstitute Department of Neurology, Seoul National University Hospital, Seoul, Korea.
Yun J KimILSONG Institute of Life Science, Hallym University, Hallym Institute of Translational Genomics and Bioinformatics, Department of Neurology, Hallym University Sacred Heart Hospital, Gangwon, Korea.
Masato KuboLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Suzanne LesageINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
Juei Jueng LinDepartment of Neurology, Chushang Show-Chwan Hospital, Nantou, Taiwan; Department of Neurology, Chung-Shan Medical University Hospital, Taichung, Taiwan.
Timothy LynchThe Dublin Neurological Institute at the Mater Misericordiae University Hospital, and Conway Institute, University College Dublin, Dublin, Ireland.
Peter LichtnerHelmholtz Zentrum München, German Research Centre for Environmental Health (Gmbh), Neuherberg, Germany.
George D MellickEskitis Institute for Cell and Molecular Therapies, Griffith University, Queensland, Australia.
Vincent MokTherese Pei Fong Chow Research Center for Prevention of Dementia, Faculty of Medicine, The Chinese University of Hong Kong, Department of Medicine & Therapeutics, Clinical Neurology Research Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong.
Karin E MorrisonFaculty of Medicine, University of Southampton, Southampton, UK.
Aldo QuattroneInstitute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy; Department of Medical Sciences, Institute of Neurology, University Magna Graecia, Catanzaro, Italy.
Wataru SatakeDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.
Peter A SilburnUniversity of Queensland Centre for Clinical Research, Herston, Australia.
Leonidas Stefanis2nd Neurology Clinic, University of Athens, Attikon Hospital, Athens, Greece; Divisions of Basic Neurosciences and Cell Biology, Biomedical Research Foundation of Academy of Athens, Athens, Greece.
Joanne D StocktonNeurosciences Department, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Eng King TanDepartment of Neurology, Singapore General Hospital, National Neuroscience Institute, Singapore; Programme in Neuroscience and Behavior Disorders, Duke-NUS Graduate Medical School, Durham, NC, USA.
Tatsushi TodaDivision of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.
Alexis BriceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
Christine Van BroeckhovenNeurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium.
Ryan J UittiDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Karin WirdefeldtDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Zbigniew WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Georgia XiromerisiouDepartment of Neurology, Faculty of Medicine, University of Thessaly and Institute of Biomedical Research and Technology, CERETETH, Larissa, Greece.
Demetrius M MaraganoreDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, USA.
Thomas GasserDepartment of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Science Research, University of Tuebingen, Tuebingen, Germany.
Rejko KrügerDepartment of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Science Research, University of Tuebingen, Tuebingen, Germany; Clinical and Experimental Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg City, Luxembourg; Centre Hospitalier de Luxembourg (CHL), Luxembourg City, Luxembourg.
Matthew J FarrerDjavad Mowafhagian Centre for Brain, University of British Columbia, Vancouver, British Columbia, Canada.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA; School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
Manu SharmaCentre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tuebingen, Tuebingen, Germany; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Science Research, University of Tuebingen, Tuebingen, Germany. Electronic address: manu.sharma@uni-tuebingen.de.
GEOPD Consortium
Helmholtz Zentrum München · DEKobe University · JPUniversity of Liège · BEUniversity of Tübingen · DEVIB-UAntwerp Center for Molecular Neurology · BEWinnMed · USAcademy of Athens · GRCenter for Research and Technology Thessaly · GRCentre Hospitalier de Luxembourg · LUCentre National de la Recherche Scientifique · FRChung Shan Medical University Hospital · TWGriffith University · AUHallym University Sacred Heart Hospital · KRInstitute of Molecular Bioimaging and Physiology · ITJuntendo University · JPKarolinska Institutet · SEMater Misericordiae University Hospital · IEMayo Clinic in Florida · USNational and Kapodistrian University of Athens · GRNational Research Council · IT
Funding
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9MSupplement-ES10751 (Molecular Epidemiology of PD)R01ES010751 · NIEHS · MAYO CLINIC ROCHESTER · PI MARAGANORE, DEMETRIUS MICHAEL · 2000 to 2010
$9.2MNeuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7MPD iPS Cell Line Research ConsortiumRC2NS070276 · NINDS · MCLEAN HOSPITAL · PI ISACSON, OLE · 2009 to 2010
$3.8MBiomarkers for Preclinical Parkinson's diseaseR01NS057567 · NINDS · UNIVERSITY OF WASHINGTON · PI ZHANG, JING · 2008 to 2012
$3.1MUnderstanding the role of MAPT in Parkinsonian disordersR01NS078086 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSS, OWEN A · 2012 to 2016
$1.7MMedical Research CouncilNIA NIH HHS U01 AG045390NIEHS NIH HHS R01 ES010751NINDS NIH HHS P50 NS072187NINDS NIH HHS R01 NS057567NINDS NIH HHS R01 NS078086NINDS NIH HHS RC2 NS070276
Abstract
A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16 loci influences risk of development of Parkinson's disease (PD). Our study examines the proposed interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multicenter series of PD patients (7715) and controls (8261) from sites participating in the Genetic Epidemiology of Parkinson's Disease Consortium. Our data does not support a strong direct interaction between LRRK2 and PARK16 variants; however, given the role of retromer and lysosomal pathways in PD, further studies are warranted.
Indexed as
Genetic Association StudiesMulticenter Studies as TopicEpistasis, GeneticGenetic LociGenetic Predisposition to DiseaseGenetic VariationHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseRiskLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanGenetic epidemiologyLRRK2PARK16Parkinson's disease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.